.-The use of computational models to predict drug-induced changes in the action potential (AP) is a promising approach to reduce drug safety attrition but requires a better representation of more complex drug-target interactions to improve the quantitative prediction. The blockade of the human ether-a-go-go-related gene (HERG) channel is a major concern for QT prolongation and Torsade de Pointes risk. We aim to develop quantitative in-silico AP predictions based on a new electrophysiological protocol (suitable for high-throughput HERG screening) and mathematical modeling of ionic currents. Electrophysiological recordings using the IonWorks device were made from HERG channels stably expressed in Chinese hamster ovary cells. A new protocol that delineates inhibition over time was applied to assess dofetilide, cisapride, and almokalant effects. Dynamic effects displayed distinct profiles for these drugs compared with concentration-effects curves. Binding kinetics to specific states were identified using a new HERG Markov model. The model was then modified to represent the canine rapid delayed rectifier K ϩ current at 37°C and carry out AP predictions. Predictions were compared with a simpler model based on conductance reduction and were found to be much closer to experimental data. Improved sensitivity to concentration and pacing frequency variables was obtained when including binding kinetics. Our new electrophysiological protocol is suitable for high-throughput screening and is able to distinguish drug-binding kinetics. The association of this protocol with our modeling approach indicates that quantitative predictions of AP modulation can be obtained, which is a significant improvement compared with traditional conductance reduction methods. computational modeling; human ether-a-go-go-related gene ion channel; drug-binding kinetics; QT prolongation; Torsades de Pointes arrhythmia WHEN NEW DRUGS are developed, there is always a concern regarding the propensity of the new drug to induce proarrhythmic effects (9). One particular arrhythmia that has plagued the pharmaceutical industry since the early 1980s is Torsades de Pointes, a rare arrhythmia not readily observed during clinical trials or postmarketing monitoring that may lead to ventricular fibrillation and sudden cardiac death (21). It is therefore a major safety issue, which led to the market removal of many drugs [including the antihistamine terfenadine (30) and the gastroprokinetic drug cisapride (41)] that were shown to block the human ether-a-go-go-related gene (HERG) channel and prolong the QT interval on the ECG (37). It is not surprising then that current regulatory guidance requires evaluating the ability of drug candidates to prolong the human QT interval (8a). To identify this anomaly, assessments of drug effects on the HERG channel and action potential (AP) are often carried out early in drug discovery (7). The detection of drug-induced AP repolarization delay raises a warning flag regarding the potential QT/Torsades de Pointes risk and allows for more informed decision making at an early stage of a research and development project (2).
WHEN NEW DRUGS are developed, there is always a concern regarding the propensity of the new drug to induce proarrhythmic effects (9) . One particular arrhythmia that has plagued the pharmaceutical industry since the early 1980s is Torsades de Pointes, a rare arrhythmia not readily observed during clinical trials or postmarketing monitoring that may lead to ventricular fibrillation and sudden cardiac death (21) . It is therefore a major safety issue, which led to the market removal of many drugs [including the antihistamine terfenadine (30) and the gastroprokinetic drug cisapride (41) ] that were shown to block the human ether-a-go-go-related gene (HERG) channel and prolong the QT interval on the ECG (37). It is not surprising then that current regulatory guidance requires evaluating the ability of drug candidates to prolong the human QT interval (8a) . To identify this anomaly, assessments of drug effects on the HERG channel and action potential (AP) are often carried out early in drug discovery (7) . The detection of drug-induced AP repolarization delay raises a warning flag regarding the potential QT/Torsades de Pointes risk and allows for more informed decision making at an early stage of a research and development project (2) .
Estimating drug potency for HERG channels can be done using various techniques, but the relatively recent introduction of the IonWorks plate-based device has rendered electrophysiological assays popular (28) . Because new drugs might also modulate other ion channels, discrepancies between HERG block and AP modulation due to multichannel block may exist (22) . Nevertheless, even in the presence of selective HERG blockers there is still a requirement of extrapolating the HERG assessed concentration-dependent inhibition to the actual risk of arrhythmia. This can be done for instance by defining safety margins around the concentration value found to decrease the channel activity by 50% in the assay (IC 50 ) (31) . This approach, which is rather arbitrary even for a pure selective HERG blocker, is all the more arguable when several ion channels are affected. To better interpret the integrated drug effect on various ion channels, computational AP models can be used (8, 25) . In these approaches, potency data are directly integrated within the model by reducing conductance in accordance with measured concentration-effect (C-E) curves. Nevertheless, drug inhibition of ion channels remains a dynamic process where binding and unbinding events occur over time (5, 14) . Therefore, C-E curve data may not satisfactorily account for the degree of ion channel inhibition reached in various conditions and might sometimes explain unsatisfactory quantitative prediction (8) . Here we show that by use of the IonWorks device, but with an improved voltage protocol and additional modeling techniques, it is possible to derive data on binding kinetics and improve AP predictions by using highthroughput technology. We demonstrate that if based on C-E curve data only, dofetilide-, cisapride-, and almokalant-induced changes in the AP can be severely underestimated.
MATERIALS AND METHODS

Cell Culture
HERG expressing Chinese hamster ovary K1 (CHO) cells were grown to semiconfluence at 37°C in a humidified environment (5% CO 2) in F-12 Ham medium containing L-glutamine, 10% FCS, and 0.6 mg/ml hygromycin (all Sigma-Aldrich). Before use, the monolayer was washed using a prewarmed (37°C) 4-ml aliquot of Versene 1:5,000 (Invitrogen). After aspiration of this solution, the flask was incubated at 37°C in an incubator with a further 4 ml of Versene 1:5,000 for a period of 5 min. Cells were then detached from the bottom of the flask by gentle tapping, and 8 ml of Dulbecco's PBS containing Ca 2ϩ (0.9 mM) and Mg 2ϩ (0.5 mM) (Invitrogen) was then added to the flask and aspirated into a 15-ml centrifuge tube before centrifugation (50 g for 2 min). A 0.5-ml aliquot of cell suspension was removed from the centrifuge tube and diluted with 0.5 ml of the Dulbecco's PBS. The number of viable cells (based on trypan blue exclusion) was determined in an automated reader (Cedex; Innovatis). After centrifugation, the supernatant was discarded and the pellet gently resuspended in an appropriate volume of PBS that would give a desired final cell concentration of ϳ200 -250 ϫ 10 3 cells/ml.
Electrophysiology: IonWorks
The IonWorks device for high-throughput screening was used for all electrophysiological recordings (33) . The reservoirs in the buffer and cells positions were loaded with 4 ml of PBS and 4 ml of the CHO-HERG cell suspension, respectively. A 96-well plate (12 ϫ 8, V-bottom, Sun Sri Plate ϩ glass coated) containing the compounds to be tested (at 3-fold above their final test concentration) was placed in the plate 1 position. A PatchPlate was clamped into the PatchPlate station. Compounds were freshly prepared before the experiment. The 96-well plate had eight rows (rows A to H). Row H contained the highest concentration (final concentration 33.3 M). A 10-fold dilution was made for the following row, then one-third of log dilution for the other rows and finally another 10-fold dilution for the last row. Once the experiment was started, the fluidics-head (F-head) added 3.5 l of PBS to each well of the PatchPlate and its underside was perfused with internal solution that had the following composition (in mM): 100 K-gluconate, 40 KCl, 3.2 MgCl2, 3 EGTA, and 5 HEPES (all Sigma-Aldrich; pH 7.25-7.30 using 10 M KOH). After prime and debubble, the electronics-head (E-head) then moved round the PatchPlate performing a whole test (i.e., applying a voltage pulse to determine whether the hole in each well was open). The F-head then dispensed 3.5 l of the cell suspension described above into each well of the PatchPlate, and the cells were given 200 s to reach and seal to the hole in each well. After this, the E-head moved round the PatchPlate to determine the seal resistance obtained in each well. Next, the solution on the underside of the PatchPlate was changed to access solution that had the following composition (in mM): 140 KCl, 1 EGTA, 1 MgCl2, and 20 HEPES (pH 7.25-7.30 using 10 M KOH) plus 100 g/ml of amphotericin B (Sigma-Aldrich). After 9 min for patch perforation was allowed to take place, the E-head moved round the PatchPlate, 48 wells at a time, to obtain HERG current measurements. For the biophysical voltage protocols no postcompound measurements were made. For drug investigations, after these precompound measurements the F-head added 3.5 l of solution from each well of the compound plate to four wells on the PatchPlate (the final DMSO concentration was 0.33% in every well). This was achieved by moving from the most dilute to the most concentrated well of the compound plate to minimize the impact of any compound carry-over. After ϳ3.5 min of incubation, the E-head then moved around all 384 wells of the PatchPlate to obtain postcompound HERG current measurements. In this way, noncumulative concentration effect data were produced where the effect of each concentration of the test compound was based on recording from between 1 and 12 cells. Voltage offsets were adjusted based on the offset obtained for preliminary experiments. The current signal was sampled at 2.5 kHz. Distorted records were discarded, and the average decrease in the assay baseline between pre-and postcompound estimated from vehicle was used to correct postcompound curves. The n numbers correspond to the number of cells that were successfully patched during an experiment.
Biophysical Voltage Protocols
Holding potential was Ϫ80 mV (20 s). Steps (80 ms each) to Ϫ70 mV and back to Ϫ80 mV were then applied to estimate leak currents. The command voltage then continued as follows.
Protocol 1 (activation curve). Potential was held at Ϫ80 mV for 2 s and then a step to a voltage V test was applied for 4 s. Another step to Ϫ80 mV for 2 s was added afterward. The protocol was applied 10 times with Vtest ranging from Ϫ70 mV to ϩ70 mV. Peak values upon repolarization to Ϫ80 mV were used to build the activation curve by normalizing to the value obtained with Vtest ϭ ϩ70 mV.
Protocol 2 (activation time course). A tail envelope protocol was used to elucidate activation kinetics. The potential was held at Ϫ100 mV for 3 s and then a step to Vtest for t1 was applied. Another step to Ϫ100 mV for 3 s was applied followed by another step to Vtest for t2 Ͼ t1. The process was repeated eight times for the eight different durations (t1 to t8). The activation time course was obtained by taking peak values upon each repolarization to Ϫ100 mV.
Protocol 3 (deactivation time course, inactivation curve, and reactivation rates). Potential was held at Ϫ80 mV for 2 s and then a step to ϩ60 mV was applied for 4 s. Another step to a voltage Vtest for 3 s was added afterward. The protocol was applied seven times with Vtest ranging from 0 to Ϫ90 mV (for the inactivation curve, 9 times with Vtest ranging from Ϫ100 to ϩ60 mV). Another step to Ϫ80 mV for 4 s was added afterward. Peak values obtained upon repolarization to Vtest were used to build the inactivation curve. The initial current shape was used to generate reactivation rates by fitting a single exponential function. The second part of these currents (after the peak) was used to derive the deactivation time course.
Protocol 4 (inactivation rates). Potential was held at Ϫ80 mV for 2 s and then a step to ϩ60 mV was applied for 5 s. Then a brief step at Ϫ100 mV lasting 6 ms was applied before stepping to a voltage Vtest for 4 s. Another step to Ϫ80 mV for 4 s was added afterward. The protocol was applied nine times with Vtest ranging from Ϫ30 to ϩ50 mV. The initial part of the current shape obtained upon depolarization to Vtest was used to derive inactivation rates by fitting a single exponential function.
Drug Screening Voltage Protocols
The potential was initially held at Ϫ70 mV for 20 s. Steps (80 ms each) to Ϫ70 mV and back to Ϫ80 mV were then applied to estimate leak currents. Currents were leak-subtracted based on this estimate. The potential was then held for an additional 100 ms at Ϫ70 mV before applying a depolarization step to ϩ40 mV. The command voltage continued as follows.
Typical screening protocol. The depolarization was kept at ϩ40 mV for 1 s and then a 2-s step to Ϫ30 mV and finally a 500-ms step to Ϫ70 mV were applied. The pre-and postscan HERG current magnitude was measured automatically from the leak-subtracted traces by the IonWorks HT software by taking a 40-ms average of the current during the initial holding period at Ϫ70 mV (baseline current) and subtracting this from the peak of the tail current response. The degree of inhibition of the HERG current was assessed by dividing the postscan HERG current by the respective prescan HERG current for each well.
New screening protocol. The depolarization was kept for 25 ms and then a 10-ms step to Ϫ100 mV was applied. Another 50 ms step to ϩ40 mV was applied, followed again by a 10-ms step to Ϫ100 mV. Then a 100-ms step to ϩ40 mV and a 10-ms step to Ϫ100 mV were applied. After that a 200-ms step to ϩ40 mV and a 10-ms step to Ϫ100 mV were applied 20 consecutive times. Finally, a 2-s step to Ϫ30 mV was applied. Peak values at the beginning of each step to ϩ40 mV were measured automatically and used to generate curves of drug effects over time. The profile of inactivation during the last depolarization to ϩ40 mV was also measured and used in the modeling process.
Electrophysiology: Optical Assay and Sharp Electrode
AP traces for the optical assay were obtained from the work of Davies et al. (8) , and a thorough description of the experimental conditions can be found there. Briefly, APs from left ventricular midmyocardial myocytes (LVMMs) were evoked by electrical field stimulation at 1-s cycle length, and illumination with UV light was restricted to 5 s every 4 min to limit photodamage, at which time AP measurements were recorded at physiological temperature for each experimental condition (37 Ϯ 0.3°C). After exposure to standard myocyte Tyrode solution, then standard myocyte Tyrode solution containing vehicle (0.1% DMSO), cumulative C-E curves to a compound were constructed over the nominal concentration range. Experimental condition (e.g., perfusate solution) was changed every 4 min. Fluorescent data were acquired directly to hard disk using a Digidata 1322A computer interface and pCLAMP software and sampled at 10 kHz. AP duration (APD) data were averaged from five traces. Any drug effects were compared with data in the presence of vehicle (0.1% DMSO).
AP traces for the sharp electrode assay were obtained from the work of Abi-Gerges et al. (1) , and a thorough description of the experimental conditions can be found there. Briefly, LVMMs APs were recorded with glass micropipettes filled with 3 M KCl, with tip resistances between 20 and 40 and 10 and 18 M⍀, respectively. The micropipette was connected to the headstage of a MultiClamp 700A amplifier (Axon Instruments, Union City, CA). AP signals from LVMMs were acquired using Clampex 9.2 (Axon Instruments) and AP software (Notocord HEM 3.4 or 3.5; Notocord Systems S.A., Croissy Sur Seine, France), respectively, at pacing frequencies of 1 and 0.5 Hz. The temperature in the recording chamber was maintained at 37.4 Ϯ 0.1°C. A stabilization period was allowed before the experimental protocol was carried out. After the stabilization period, data acquisition was commenced, providing APs were typical of those observed in dog LVMMs. AP stability was assessed again in the first 5-10 min of recording in the standard Tyrode solution at a pacing frequency of 1 Hz. After exposure to the standard Tyrode solution, the same sequence was repeated during perfusion of the same preparation with standard Tyrode solution containing vehicle (0.1% DMSO), then with four ascending concentrations of drug to form a cumulative CE curve over the nominal concentration range.
Simulations
Two Markov models (11), one for HERG at room temperature (20°C) and one for dog rapid delayed rectifier K ϩ current (IKr) in M cells at 37°C were developed.
Model of HERG at room temperature. The first of these models reproduces the biophysical experimental data generated at room temperature with our stable CHO cell line, which expresses HERG (Fig. 2) . The model includes two closed (C1, C2) and one open (O) and corresponding inactivated (IC1, IC2, IO) states ( Fig. 2A) . The forward and backward rates of transition from one state to another were determined based on our experimental biophysical data ( Fig.  2B-F) . The model rates were optimized using the Simplex algorithm (19) (Matlab R2009a) and are given in Table 1 . This model was complemented by two bound states O* and IO* to model drug binding by using additional 2 or 4 parameters, which were drug specific to model four possible configurations for each drug (Fig. 1) . To increase the chance of obtaining a satisfactory solution, the Simplex algorithm was run for each drug and each configuration starting from several combinations of initial parameters. For models with one bound state (O* or I* only), four different initial guess were used (permutations of kf ϭ 5 ϫ 10 Ϫ2 ms Ϫ1 or kf ϭ 2.5 ϫ 10 Ϫ4 ms Ϫ1 and K ϭ 2.5 ϫ 10 Table 2 . Table 3 . The model for I Kr in drug presence was complemented by two bound states (O* and IO*). The structure of the model for the bound states (O* and IO* connected or not) and the rates and affinities for the transitions IC↔IC* and IO↔IO* were the same as for the HERG model at room temperature.
For all models, microscopic reversibility (14) was ensured by fixing the products of forward and reverse transition rates of closed loops. Mathematical equations for the Markov models were constructed using an in-house Cϩϩ code and run on a desktop machine (Intel Xeon @ 2.27GHz). Our code integrates the CVODE ODE solver package, which is freely available (6). Ϫ1 to fit the non-normalized activation curve of Fig. 6A . Equations in the original AP Cϩϩ code were rewritten to numerically integrate the whole model using the CVODE ODE solver package. Pacing was induced as in the original Hund and Rudy model by applying a current of Ϫ80 A(F) Ϫ1 for 1 ms at the required frequency. The number of pacing cycles required for the AP model to converge was based on AP duration convergence.
RESULTS
To model the activation and faster inactivation of the HERG channel, several states are required to represent stages through which the channel cycles. Figure 2A (Fig. 2B ). An activation curve derived from our experiments and simulation results are shown in Fig. 2C . A tail envelope protocol was used to generate the time course of activation at several voltages (Fig. 2B ) while deactivation kinetics (Fig. 2D) were obtained through an additional protocol. Experimental and simulated inactivation curves shown in Fig. 2E indicate that a fraction of the HERG population is almost always inactivated within the physiological voltage range. A small discrepancy was seen between simulated and experimental curves for voltages above 0 mV (Fig. 2E ), but it is believed this was due to a background current in the assay [model results are in agreement with published data (23, 34, 40) ]. Figure 2F shows variation in time scales for inactivation/reactivation in the range 3 to 14 ms, which is one to two orders faster compared with activation [a well-known HERG feature (23, 34, 40) ]. This specific point, together with the fact that at positive voltages HERG channels tend to be mostly inactivated, renders investigation of HERG inhibition by drugs over time difficult. In agreement with published data (23, 34, 40) , our results confirm the ability of the IonWorks device to generate satisfactory biophysical data (33) . Measured characteristics were integrated into the HERG Markov model, which was later used to elucidate drug effects measured via this platform. Figure 2G shows how the model simulates experimental recordings of HERG current. Figure 3A shows the voltage step protocol that is being routinely used in our laboratories for HERG screening. Upon repolarization, the amount of block was estimated based on the magnitude of the tail current produced and typical C-E curves for the three drugs investigated in this study are shown in Fig.  3B . Experimental IC 50 values for dofetilide, almokalant, and cisapride were found to be 190 nM [95% confidence interval (CI) ϭ 155-234 nM], 508 nM (95% CI ϭ 376 -685 nM), and 207 nM (95% CI ϭ 155-277 nM), respectively. Although this method has the benefit of simplicity, it fails to highlight the dynamics of drug binding over time and does not ensure that the level of block obtained corresponds to a true equilibrium value (longer depolarization steps may be required to reach this equilibrium). Although a decrease in current amplitude was seen in the presence of 158 nM cisapride during depolarization to ϩ40 mV, this decrease did not reflect HERG inhibition over time since the current produced was in fact masked by the combined presence of substantial inactivation and background currents. This can be recognized on the one hand by the relative weakness of the cisapride-induced decrease (22%) during depolarization to ϩ40 mV (sometimes even absent) that was not consistent with the decrease in the tail current (58%). On the other hand, the evolution profile over time does not necessarily reflect the binding process. For instance, a time-dependent increase in channel block for cisapride inhibition was observed by using a different stimulation protocol (Fig. 4E) .
To identify drug binding over time, a new voltage protocol was developed that overcomes the issues highlighted above (Fig. 4A) . Starting from a resting potential of Ϫ70 mV, the cell membrane was initially depolarized to ϩ40 mV. Once the cell was depolarized, depolarization was not maintained but instead a fast repolarization to Ϫ100 mV was regularly applied. During this short repolarizing step (10 ms), inactivation was almost fully removed and, when the membrane was depolarized again, the amount of unblocked open channels was estimated using the peak value of the current produced (Fig. 4B) . This depolarization/repolarization process was regularly repeated and allowed for a dynamic assessment of drug binding by tracking generated peak values. Because the strong current created upon repolarization was more substantial than any background current, contamination by the latter was minimized. Both the regular voltage step (black lines in Fig. 4A-D) and new (red lines in Fig. 4A-D ) protocols were simulated with our HERG model. The currents obtained were similar except for the strong peaks that occurred during the regular depolarization/repolarization process (Fig. 4B) . Figure 4C shows that the continuous decrease of the amount of ion channels in the closed state followed a similar course for both protocols since the new protocol only introduces fast transient peaks, which arise when reactivating the ion channels (Fig. 4D) . These results support the fact that the depolarization/repolarization step introduced minimal interaction with the activation process itself, which allows exposure to the binding site. Figure 4E shows an experimental record obtained with this new protocol in control condition and in the presence of 74 nM cisapride. The symbols highlight the peak current obtained upon repolarization, which can be tracked for each drug at various test concentrations. Figure 5 shows the data obtained with this modified voltage protocol in the presence of dofetilide, cisapride, and almokalant when the peak values are extracted as in Fig. 4E . In control conditions a current that develops exponentially over time was obtained and corresponded to HERG activation. In the presence of compounds, two different profiles were identified. For dofetilide, HERG activation was found to be decreased in magnitude at all time points without showing major morphology alterations. In contrast, the decrease was accentuated with cisapride over time and indicated a sustained block of HERG channels by the compound. For almokalant at low concentrations there was an apparent reduction of magnitude at all time points, while a time-dependent increase in channel block was seen at higher concentrations. To model drug effects with our HERG model, we complemented O and IO states with an open (Fig. 1) . Figure 5 , A-C, shows that by our HERG model being complemented with the bound states and by the use of an appropriate set of rates and affinities for binding and unbinding, the experimental data were satisfactorily reproduced over the entire range of concentrations assessed.
For almokalant and cisapride, a slight overshooting of the curve above control conditions was seen experimentally with the first concentration. This could be due to some agonist effect and was taken into account by a small increase in conductance of 5% and 16%, respectively. Every time that a repolarization/ depolarization step was applied, a peak was produced (HERG reactivation), which quickly disappeared after an exponential decrease (HERG inactivation). We observed that inactivation became faster with increased block, and therefore we extracted the inactivation profile induced by the last repolarization/ depolarization step (Fig. 5D) to further constrain the parametrization of our models with drug-bound states. Rates for the three drugs are given in Table 2 . Binding to dofetilide rather than to almokalant and cisapride was found to be faster. However, all three drugs were found to have a higher affinity for the open state compared with the inactivated state.
Our model for HERG at 20°C, which we used to elucidate drug action, corresponds to screening conditions. As HERG activation and inactivation kinetics become faster with increasing temperature, we have modified the Markov model of HERG to reproduce canine I Kr at 37°C in midmyocardial cells before integrating the ion channel model within AP simulations. The inset in Fig. 6A shows the structure of the I Kr Markov model. Here only one closed state is used since the experimental activation data used to build the model (20) (same as in the original formulation of the AP model) did not allow distinguishing transitions between closed states. C and O states were modeled with corresponding IC and IO states. In the absence of drug binding and if inactivation rates are neglected, this Markovian model is equivalent to the original Hodgkin-Huxley formulation implemented in the Hund and Rudy AP model. Nevertheless, our mathematical formulation now also allows easy integration of drug-binding results elucidated at 20°C. Figure 6 shows experimental and simulated I Kr biophysical data for dog ventricular midmyocardial cells. When compared with data at room temperature, the activation curve was found to be similar (Figs. 2C and 6A ), whereas activation rates were one to two times faster at 37°C (Figs. 2,  B and D, and 6B ). The inactivation curve was shifted toward negative values (Ϫ22 mV; Figs. 2E and 6C), whereas inactivation rates were five to six times faster (Figs. 2F and 6D) .
We complemented our Markov model for I Kr at 37°C by O* and IO* states as for the Markov model at 20°C. Binding and unbinding kinetics used here were those obtained with the HERG model at 20°C. The modified model for I Kr in the presence of drug was then integrated into the AP model. To assess the impact of our new experimental protocol and the binding kinetics included in the I Kr model, we used a I Kr Markov model at 37°C without bound states. In this simpler model, the conductance for I Kr in the AP model was decreased according to C-E curve data generated with the full model when applying the voltage protocol shown in the inset of Fig.  3A . Figure 7 shows APD changes obtained with almokalant, dofetilide, and cisapride at various concentrations and pacing frequencies for both models. Although almokalant induced mild increases in APD with the simpler model at all frequencies, increases seen with the full model were larger. For example, at 2 Hz an increase of 33.4% was seen with the simpler model at 3 M, whereas the full model reached a similar value (32%) at a lower concentration (1 M) and predicted a more pronounced prolongation at 3 M, which evolved into alternans (variation between 21% and 105%).
For dofetilide the differences were less pronounced. At 0.1 M the full model indicated more variation over frequency space compared with the simpler model. The predicted APD increases and the amplitude of alternans were also larger for the full model. For cisapride, multichannel activity has also been included via a reduction of the conductance of the 4AP-sensitive transient K ϩ outward, the fast Na ϩ , the late Na ϩ , and the L-type Ca 2ϩ currents (I to , I Na , I NaL , and I CaL , respectively). C-E curves for conductance reductions in I to , I Na , and I NaL were taken from Davies et al. (8) , whereas reduction in I CaL was based on other published data (15a); an adjustment at 10 M was done based on the requirement of a biphasic profile at 1 Hz and 0.5 Hz (1, 7) . As for almokalant, the simpler model predicted lower increases compared with that of the full model, whereas alternans was only seen with the full model. For example, 1 M cisapride increased APD by ϳ20% with the simplified model for frequencies lower than 1.5 Hz, whereas the full model was able to generate an APD increase of 50% at 1 Hz. Note that bifurcation of contours in Fig. 7A -C was not due to long-term dynamical instability of the model. Instead, it was due to the generation of AP alternans arising from the long effective refractory period of the cell and rapid pacing. Example of simulated and experimental AP traces from sharp electrode experiments that display this behavior are shown in Fig. 7D .
We evaluate now our model predictions using independent datasets from sharp electrode and optical assay experiments. Figure 8A shows typical APs recorded with dog myocytes using the sharp electrode technique and computed with the full model at 1 Hz in the presence of different concentrations of cisapride. AP morphologies were similar, although in this particular example the initial notch obtained experimentally was more pronounced. Both data show that although the AP was prolonged with concentrations up to 1 M, the inhibition of multiple currents at 10 M reversed the APD increase and the notch and dome profile were lost. Figure 8C shows averaged APD results for the same conditions obtained via sharp electrodes, optical assay, and simulations. For the full model the initial APD increase due to I Kr inhibition was in good agreement with both experimental techniques. However, at 1 M the results obtained with the full model overestimated the prolongation, since experimentally inhibition of other ion channels was found to be strong enough to induce a decrease in the APD. The combined inhibitory effect of I Na , I NaL , I CaL , and I to was nevertheless implemented here by simply decreasing conductances based on published data (8, 15a) . For the simpler model, the initial APD increase was clearly underestimated. Next, we assessed dofetilide effects. Figure 8B shows excellent agreement between experimental and modeled AP signals in the presence of 1 M dofetilide at 1 Hz. On average, the simpler model was also able to predict results similar to the full model although at 0.1 M the full model produced better predictions. The magnitude of simulated APD increases obtained was closer to optical results than to sharp electrodes at 0.01 M and 0.1 M. But at 1 M the models indicated an increase closer to the sharp electrode data, which shows an unexpected decrease. This decrease was due to the fact that the published experimental data at 1 M did not evoke strong APD increases for which the AP signal was lost due to early afterdepolarizations and triggered activity, and as a consequence a bias toward less prolonging AP was present in the experimental data. For almokalant (Fig. 8G) , optically measured APD increases at 1 Hz were better predicted with the full model, whereas the simpler model was again less satisfactory. It is also interesting to compare results obtained at the reduced frequency of 0.5 Hz. Cisapride data indicated a similar trend for experimental data and data simulated with the full model, which was not the case with the simpler model predictions. Similarly, dofetilide data at 0.5 Hz were in good agreement with data generated using the full model, whereas the simpler model was slightly less predictive at intermediate concentrations as for 1-Hz pacing. Experimental data at 0.5 Hz was not available for almokalant.
DISCUSSION
This article shows how neglecting drug-binding kinetics at the level of cardiac ion channels can lead to substantial underestimation of in-silico cardiac risk assessments at the ventricular AP level. We have introduced a new method that allows this difficulty to be overcome for the HERG channel and that can be realistically implemented by interested parties using modern high-throughput electrophysiological devices and computational models. We have obtained quantitative predictions for drug-induced modulation by cisapride, dofetilide, and almokalant while making use of only one voltage protocol and a modeling strategy, which together, can be fully automated.
From Ion Channel to AP Modulation
To reduce the risk of developing potential QT prolonging drugs, pharmaceutical industries have developed screening strategies to try detecting hazardous drugs early in the drug discovery process (8a). Thus assessing the effects of candidate drugs against a panel of cardiac ion channels is now a common practice. Concentration-dependent equilibrium values for ion channel inhibition represented as C-E curves are used in conjunction with empirical safety margins to assess the drug-related risk to QT prolongation (31) . A more rational approach may involve the use of an AP model to assess the integrated effects of ion channel inhibition (25) and predict the outcome of AP assays, which are run only later in the drug discovery process. Recently, Davies et al. (8) have developed a comprehensive model (from assay to AP predictions) that predicts APD modulation of ventricular midmyocardial cells based on a panel of five ion channels and corresponding C-E curve data. Although the predictivity of their model was qualified as good in terms of compound activity, it was found that the model lacked satisfactory quantitative predictivity. Among potential reasons the absence of modeling state-based interaction between ion channel and drug was identified. To develop improved in-silico ion channel models, drug action over time is required while C-E curves only represent induced block at supposed equilibrium. We addressed this issue by introducing a new experimental protocol and computational models. Due to its importance in a screening cascade, we developed an experimental and modeling approach around the HERG channel.
Improved Drug Profiling
Our biophysical and computational analyses show that a single voltage protocol could be applied systematically to retrieve drug- binding kinetics data. The effects of dofetilide, cisapride, and almokalant were clearly distinguished based on their action against the HERG channel over time (Fig. 5) . In contrast, distinction was blurred in the C-E curves (Fig. 3B) since it relied only on translation in concentration space. Because C-E curves cannot differentiate the diversity in terms of the kinetics of drug action, they tend to group all drugs with similar IC 50 values into the same category. This is problematic since C-E curves and IC 50 values are likely to depend on the voltage protocol (24, 36) , cell types, and/or technologies (29) used and do not provide information in terms of drug effects over time. In contrast, kinetic information is intrinsic and does not depend a priori on the protocol used to elucidate it. It also naturally includes dynamic effects. By integrating the binding kinetics data into our Markov model of the HERG channel, we found that computed C-E curves for almokalant and cisapride were in excellent agreement with the ones determined experimentally, whereas the curve obtained for dofetilide indicated a lower IC 50 value (Fig. 3B) . Note that this slight discrepancy in the case of dofetilide is not due to the mathematical model, but instead is a consequence of the fact that different compound plates were used for the standard protocol (symbols) and the new protocol (on which the model is based). Thus, to a reasonable extent, our new protocol not only brings additional information in terms of binding kinetics but also includes the information traditionally retrieved from standard tail current protocols.
C-E Curves-Based Versus Kinetics-Based Predictions
Assessing the effects of novel drugs on the AP is a recommended practice in the drug discovery process (8b). For several strategic reasons (13) , this is done in our laboratory using dog ventricular myocytes. However, recording the AP from ventricular myocytes is more limited in its throughput and demands on primary tissue and is performed only later in the drug discovery process. By integrating kinetic values generated during early safety assessment into a Markov canine I Kr model at 37°C and incorporating this model into a modified version of the Hund and Rudy AP model (15) , our data show dofetilide-, cisapride-, and almokalant-induced AP changes were satisfactorily predicted in a concentration-dependent manner and at several frequencies. In contrast, modeling drug effects by reducing ion channel conductance is a simpler approach that can rely on a straightforward processing of experimental data in their currently available format. Our data show significant differences between AP predictions generated using the C-Ebased conductance reduction model compared with those based on our full Markov model that integrates drug-binding kinetics. Striking difference was particularly seen with almokalant and cisapride for which the incorporation of kinetics data into the model led to the prediction of larger changes in APD (up to more than 2 times higher) and incidence of alternans that were only seen with our full model (Figs. 7 and 8) . These results indicate that usage of a standard voltage protocol (inset of Fig.  3A ) may lead to underestimating changes in APD. (35) . However, the fact that the drug is not necessarily assumed to be trapped in the ion channel pore in our model and various structures were investigated during our optimization process precluded the simplifications used in Saiz et al. (32) study.
Previous Drug-Binding Models
Limitations
We have modeled binding to activated states only as this is likely to be the case with HERG, which has a surprisingly large cavity (26) . Other, less common possibilities exist, but our limited experimental data when using high-throughput screening (there are technological limitations) precludes extra sophistication. For instance, the possibility of binding to closed states cannot be discarded and some amount of tonic block may be present before ion channel opening. Additionally, other modes of action are known (27) , which can be easily integrated into our Markov models but would require additional experimental data. Therefore, the specific example cases investigated here appear to be reasonably modeled, but alternative binding schemes cannot be excluded, particularly for other drugs that might not be represented in a similar way. Although our experimental and simulated HERG data were obtained at room temperature, variations in biophysical kinetics were accounted for in the AP simulations at 37°C, whereas drug-binding kinetics were assumed to remain unchanged. When comparing C-E curves generated with our models at room temperature and 37°C, we found no significant IC 50 variations (Fig. 3) . This is in agreement with experimental studies that also reported minor differences between IC 50 values at room temperature and 37°C (12, 18, 38) . Hence, major kinetics changes seem to be operated more at the level of the intrinsic biophysical properties of HERG rather than at the level of drug binding as modeled in this investigation. Adjustments based on Q 10 temperature coefficients could be used to model temperature effects but are subject to a satisfactory way of estimating them (14) . An obvious approach to tackle the impact of temperature might be the development of a screening device that operates at physiological temperature.
Future of Our Method
Compounds with agonist effects were not considered in this work as in the study of Davies et al. (8) . Our new protocol can be used to assess agonist effects over time and translate them into kinetics data, but our HERG model should be modified accordingly by defining for instance conducting bound states with increased conductance. Also, multichannel block is critical regarding integrated effects on the AP. This aspect has been addressed in Davies et al. (8) . Obviously, during screening, effects on other ion channels can (and should) be added [we currently screen against 5 different ion channels from which we derive dose-response curves; see Davies et al. (8) ]. In the future, other ion channels might also been screened according to their dynamic effects rather than only their tonic dose-response curve.
Although several previous studies have suggested approaches to identify mechanistic information and model parameters based on complex series of voltage steps (11, 24, 43) , they cannot be implemented using IonWorks technology and only one round of experiments as for our combined approach presented here (speed and cost effectiveness are critical for screening purposes). Typically, the IonWorks device we have used is able to generate up to 384 recordings during one experiment, which can be used to screen 10 compounds at eight different concentrations within 1 h. Automatic postprocessing can therefore lead to the generation of in-silico predictions for hundreds of drugs per day. Our approach has therefore the potential to strongly impact and modify current practice in drug safety assessment for the research community at large and the pharmaceutical audience in particular.
